334952-07-7

Usage

Uses

Used in Organic Synthesis:
Methyl 4-(2-methoxy-2-oxoethyl)-3-nitrobenzoate is used as a building block in organic synthesis for the preparation of various chemical compounds. Its unique structure and reactivity allow for the creation of a wide range of organic molecules with potential applications in various industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, methyl 4-(2-methoxy-2-oxoethyl)-3-nitrobenzoate is used as an intermediate in the synthesis of various drugs. Its versatile chemical structure enables the development of new pharmaceuticals with potential therapeutic benefits.
Used in Agrochemical Industry:
Methyl 4-(2-methoxy-2-oxoethyl)-3-nitrobenzoate is also used in the agrochemical industry as a precursor for the synthesis of various agrochemicals, such as pesticides and herbicides. Its unique properties contribute to the development of effective and environmentally friendly solutions for agricultural applications.
Used in Chemical Research:
Due to its versatile chemical structure and reactivity, methyl 4-(2-methoxy-2-oxoethyl)-3-nitrobenzoate is utilized in chemical research to explore new reactions and mechanisms. This research can lead to the discovery of novel compounds and applications in various fields, including materials science, catalysis, and environmental chemistry.

Upstream product

• 67-56-1 methanol 
• 444667-11-2 2-(4-carboxy-2-nitrophenyl)-acetic acid 
• 618-95-1 methyl 3-nitrobenzoate 
• 96-34-4 methyl chloroacetate 
• 865-47-4 potassium tert-butylate 
• 121-92-6 3-nitrobenzoic acid 
• 651747-69-2 2-(4-cyano-2-nitrophenyl)malonic acid dimethyl ester 
• 89642-49-9 4-bromo-3-nitrobenzonitrile 
• 501-89-3 4-(carboxymethyl)benzoic acid 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 99-75-2 4-methyl-benzoic acid methyl ester 
• 76469-88-0 methyl 4-(cyanomethyl)benzoate 

Downstream Products

• 1105512-80-8 methyl 2-(4-methoxycarbonyl-2-nitrophenyl)acrylate 
• 1160293-25-3 methyl 1-(2-chloroacetyl)-2-oxoindoline-6-carboxylate 
• 1160293-24-2 N-chloroacetyl-3-[methoxy(phenyl)methylene]-2-oxoindoline-6-carboxylic acid methyl ester 
• 1160293-22-0 3-[methoxy(phenyl)methylene]-2-oxoindoline-6-carboxylic acid methyl ester 
• 334952-09-9 2-Oxo-2,3-dihydro-1H-indole-6-carboxylic acid 
• 656247-17-5 nintedanib 
• 1027407-75-5 (Z)-1-acetyl-3-(ethoxy-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Indolone derivative and pharmaceutical application thereof

The invention provides an indolone derivative and pharmaceutical application thereof. The structure of the indolone derivative is shown as a formula (A). Experimental results show that the compound provided by the invention has obviously improved pharmacokinetic properties than BIBF1120, has excellent inhibition effects on VEGFR, FGFR and PDGFR, can be used as a VEGFR, FGFR and/or PDGFR inhibitor,an angiogenesis inhibitor and a drug for preventing and/or treating various tumors including pharyngeal squamous cell carcinoma, and has a wide application prospect.

Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties

Nintedanib is a novel triple angiokinase inhibitor that inhibits three growth factors simultaneously. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. In particular, deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. These efforts lay the foundation for further investigating the druggability of SKLB-C2202. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. Deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. Further research is underway.

OXINDOLE INHIBITORS OF TYROSINE KINASE

The present invention relates to new oxindole inhibitors of tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)

Inhibition of tumor angiogenesis through blockade of the vascular endothelial growth factor (VEGF) signaling pathway is a newtreatment modality in oncology. Preclinical findings suggest that blockade of additional pro-angiogenic kinases, such as fibroblast and platelet-derived growth factor receptors (FGFR and PDGFR), may improve the efficacy of pharmacological cancer treatment. Indolinones substituted in position 6 were identified as selective inhibitors of VEGF-, PDGF-, and FGF-receptor kinases. In particular, 6-methoxycarbonyl-substituted indolinones showed a highly favorable selectivity profile. Optimization identified potent inhibitors of VEGF-related endothelial cell proliferation with additional efficacy on pericyctes and smooth muscle cells. In contrast, no direct inhibition of tumor cell proliferation was observed. Compounds 2 (BIBF 1000) and 3 (BIBF 1120) are orally available and display encouraging efficacy in in vivo tumor models while being well tolerated. The triple angiokinase inhibitor 3 is currently in phase III clinical trials for the treatment of nonsmall cell lung cancer.

Substituted indolines which inhibit receptor tyrosine kinases

Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.

Substituted indolinones

The present invention relates to indolinones substituted in the 6-position of general formula wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Synthesis and photophysical characterization of a new, highly hydrophilic caging group

o-Nitrobenzyl-protected bioactive compounds are useful tools in biophysics, allowing controlled photorelease of biologically active compounds with high temporal and spatial precision. Thus, it is possible to study biological processes, such as neurotransmitter-receptor interaction, and many other processes, in much more detail than before. In this respect, these caged compounds have become established as extremely useful tools. In some cases, however, their biological properties (the caged compound should not interact with the biological system), their photochemical properties (quantum yield and kinetics of the photorelease), and their physical properties (high hydrophilicity) are not satisfactory. In order to address the last problem, we examined means to increase the hydrophilicity of caged compounds based on the o-nitrobenzyl moiety. Here, we report the synthesis and the photochemical and biological characterization of a new caged Daspartate derivative with vastly improved hydrophilicity, compared to derivatives reported previously, and satisfactory photophysical properties. Caged compounds with this improved o-nitrobenzyl group may thus represent a valuable new tool for different kinds of biophysical investigations. Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.